Everything You Need To Know About A Non-Surgical Eyelid Lift – BEAUTYcrew

Thanks to the effects of sun damage, pollution, mindless rubbing (guilty), heavy-handed makeup removal (also guilty) and ageing, the skin around your eyes is the first area to show signs of decline. Were talking wrinkles, sagging and all the good stuff that makes you look even more tired than you actually are. Cool!

While the promise of youthful, taut, post-eyelid lift skin might sound like the best option going, if youre anything like us, you'll most likely be put off by the cost, risks and downtime involved. Because guys, surgery is a big deal, and theres no going back once the procedure has been performed.

But there are other options out there. Unlike eyelid lift surgery (which is also known as a blepharoplasty), plasma eyelid lift is the latest non-surgical procedure that helps tighten the eyelid skin, minimising the effects of eye ageing. The best part? It involves no incisions and requires minimal downtime.

A plasma eyelid lift is a procedure used to tighten, lift and rejuvenate the skin on the upper eyelid, all without surgery. And just FYI while it sounds like were talking about plasma found in the blood, were actually talking about plasma as a high-energy current. The fourth state of matter, plasma is an ionised gas able to conduct a large and sustained electrical current. The sun, fire and lightning bolts are examples of plasma, explains Natalie Abouchar, registered nurse and founder of Prive Clinic.

Without touching the skin, a hand-held device (which looks like a small pen) is moved over the surface of the eyelid to tighten the skin and encourage collagen production. The pen works by ionising gases in the air to create a small electrical arc, similar to a lightning bolt, that can be used to rejuvenate problem areas without damaging the surrounding areas, says Abouchar. The pen projects an ionised, low frequency plasma arc onto the skin surface, vaporising the skin at the point of contact and resulting in an instant contraction and tightening of skin fibres.

Feeling a little bit lost? To break it down, the device basically heats the dermis in the target area (your eyelids), which then sheds post treatment, tightening the skin and allowing fresher skin to form.

The treatment is fairly versatile and can be used on all different areas of the face (such as frown lines, nasolabial folds and crows feet), and can treat a wide range of skin conditions, including laxity and loss of texture. According to Abouchar, when used on the eye region the plasma eyelid lift can effectively reduce the amount of lax skin on hooded upper eyelids. Overall, it gives the eyes a more youthful, open and awake appearance.

According to Abouchar the procedure is suitable for people who are in the early stages of eye drooping with skin types one to three (people with pale white skin, fair skin and darker white skin). If the skin above the eyes is very heavy, a surgical eyelid lift may be a more appropriate treatment. During your consultation, your doctor or nurse will analyse your skin and let you know if you are a suitable candidate for this treatment.

Topical anaesthetic cream is applied prior to the ACCOR Plasma Pen Non-Surgical Eyelid Lift. This is left on for approximately 30 minutes. The treatment is then performed by placing dots in a particular pattern on the eyelid and lateral temple region. After it is completed, a powder and setting spray is applied to cover the dots and help heal the tissue.

Most people can expect around five days of downtime in which makeup cannot be worn. Redness and swelling will occur immediately post-treatment, with swelling peaking over the two days following treatment, says Abouchar. Its important not to ice the area as the swelling is an important part of the process. There will also be noticeable dot marks in the treatment area. These tiny, pinprick dots are portions of ablated tissue, formed into scabs. These last for around four to seven days and youll need to avoid picking them or getting them wet to prevent scarring. Once the scabs have fallen off, you can resume normal activities and wear makeup to cover any redness that may remain.

Abouchar says two treatments are generally required, however, whether or not more treatments are needed will depend on the degree of laxity. The full effect of the initial treatment is visible after 12 weeks. At this point, a second tightening and lifting treatment may be performed, if required.

If the plasma eyelid lift treatment doesnt sound like your jam, dont worry theres still a bunch of other non-surgical alternatives to going under the knife. Non-surgical eye rejuvenation can be achieved with a mix of anti-wrinkle injections and dermal fillers. Injecting a neurotoxin superficially into the orbicularis oculi muscle (just under the eyebrow and lateral to the eye) and into the glabella (the frown lines) will relax the muscles responsible for a drooping eye area, explains Abouchar. This results in a lifting of the eyebrows and a fresher, more youthful appearance. Dermal fillers can also be injected into the temple and deep under the muscle on the brow to lift the eyebrows and create a more open-eyed look.

Radio frequency can also be used to lift and tighten loose skin around the eyes. Here, a combination of skin needling and radio frequency energy triggers the bodys natural healing response, thus stimulating collagen and elastin production. The radio frequency causes a thermal reaction in the tissue, resulting in tighter skin, reduced fine lines and a brighter, more radiant eye contour, says Abouchar.

Platelet rich plasma (PRP) is another non-surgical option that can be used to tighten sagging skin on the face (you can read more about whats involved in a PRP treatment here). A 100 per cent natural option, vampire injections (using your own blood) can also be used to thicken and strengthen sagging, crepey skin in the eye contour and boost collagen for a reduction in fine lines and wrinkles.

For more non-surgical treatment options, check out everything you need to know about thread lifts.

Main image credit: Getty

Original post:
Everything You Need To Know About A Non-Surgical Eyelid Lift - BEAUTYcrew

CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -…

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Click to copy

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced a partnership with Cytovia Therapeutics Inc. (Cytovia) to develop new disease treatments that leverage human stem cell research and novel gene editing techniques. NYSCF will be a key partner to Cytovia in using stem cells to advance novel therapeutic targets for cancer.

Cytovia leverages NK cells to make these novel therapeutics more specific to cancer cells. NK or natural killer cells are immune cells that scan the body and attack infected or abnormal cells, often serving as a first line of defense against cancer. CAR (chimeric antigen receptor) NK cells are genetically engineered to better locate and attack tumors. CAR NK-based treatments are currently showing promise in clinical trials and could serve as a potent and cost-efficient alternative to current immunotherapies. Establishing high-quality, stem-cell-derived NKs and CAR NKs will help improve these treatments and accelerate their path to the clinic.

The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array, the premier automated robotic platform for reprogramming adult cells into induced pluripotent stem cells (iPSCs). These iPSCs carry the genetic blueprint of the person from whom they are derived and can be turned into any cell type in the body, allowing scientists to study disease mechanisms in affected cells or modify them for use in therapeutics.

Our mission is to bring lifesaving treatments to patients around the world and we are excited to further this goal in partnership with Cytovia, says NYSCF CEO and founder Susan L. Solomon. It is critical that we collaborate with partners using our technology and expertise to bring innovative treatments to the market.

We are delighted to collaborate with the NYSCF Research Institute to develop iPSC-derived NK and CAR NK therapeutics, says Dr. Daniel Teper, CEO of Cytovia. By integrating NYSCFs world-class stem cell know-how and the precision gene-editing research conducted at the University of California San Francisco, Cytovia aims to become a leader in NK cell therapeutics for the treatment of cancer.

About The New York Stem Cell Foundation Research Institute The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 190 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array, which is used to create cell lines for laboratories around the globe. In 2019, NYSCF launched its Womens Reproductive Cancers Initiative, which aims to shift paradigms in the way these cancers are studied and treated, in collaboration with leading cancer experts across the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visit http://www.nyscf.org.

About Cytovia Therapeutics Inc. Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies. Learn more at cytoviatx.com

Contact information:CYTOVIA Therapeutics:Anna Baran-DjokovicVP, Corporate Affairs anna@cytoviatx.com

Cytovia Media Contact: Charlotte Tomic charlotte@tomiccommmunications.com Cell: 9178825243

NYSCF Research InstituteDavid McKeonChief of Staff dmckeon@nyscf.org

Continue reading here:
CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -...

Stem Cells Market Segmentation and Analysis Report, 2025 – Food & Beverage Herald

In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This post was originally published on Food and Beverage Herald

Read more:
Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald

Stem Cell Therapy Market Robust Growth Counted to 2025 – Instanews247

Stem Cell Therapy Market research now available at Industry Stats Report encompasses an exhaustive Study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends characterizing the Stem Cell Therapy industry landscape. This report also covers details of market size, growth spectrum, and the competitive scenario of Stem Cell Therapy market in the forecast timeline.

Request for Sample of this [emailprotected] https://industrystatsreport.com/Request/Sample?ResearchPostId=595&RequestType=Sample

The well-established Key players in the market are:

Gilead Novartis Organogenesis Vericel Others

This report for Stem Cell Therapy Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

Reports include the following segmentation: By Product Type Adult Stem Cells Human Embryonic Stem Cells (hESC) Induced Pluripotent Stem Cells Very Small Embryonic Like Stem CellsBy Applications Type Regenerative Medicine Drug Discovery and DevelopmentBy Technology Cell Acquisition Cell Production Cryopreservation Expansion and Sub-CultureBy Cell Therapy Autologous AllogeneicBy Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

Request Customization of this Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=595&RequestType=Customization

Some Main Reasons for Purchasing This Report:

New ways and approaches appropriate within the advancement structure of themarket.

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

More Details on this Report: https://industrystatsreport.com/Semiconductor-and-Electronics/Stem-Cell-Therapy-Market-Share/Summary

Worldwide Market Report Provides Comprehensive Analysis of:

Functional market industry outline

Up and downstream industry examination

Channels and propositions believability

Market challenge by key players

Enhancement suggestions examination

The report outlines the regulatory framework surrounding and governing numerous aspects of the market. At the end, Stem Cell Therapy industry development rival view, the industry scenario, samples, research conclusions are described. The important examination incorporated from 2014 to 2019 and till 2024 makes the report helpful assets for industry officials, promoting, sales, directors, experts, trade consultants, and others looking for key industry information with clearly given tables and charts.

More Report: https://www.marketwatch.com/press-release/smart-eyewear-technology-market-size-share-application-analysis-regional-outlook-growth-upcoming-trends-key-players-and-competitive-strategiesforecast-to-2025-2019-08-13

Read More Report:

https://www.marketwatch.com/press-release/investment-casting-market-size-segmented-by-product-type-top-manufacturers-by-end-user-industry-geography-trends-and-forecast-2025-2020-01-09

Read More Report:

https://www.marketwatch.com/press-release/surgical-anti-adhesion-products-market-2019-latest-innovations-analysis-by-key-manufacturers-commercial-sector-overview-component-industry-revenue-and-forecast-to-2025-2020-01-09

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

[emailprotected]

Follow this link:
Stem Cell Therapy Market Robust Growth Counted to 2025 - Instanews247

The Top Biotech Trends We’ll Be Watching in 2020 – Singularity Hub

Last year left us with this piece of bombshell news: He Jiankui, the mastermind behind the CRISPR babies scandal, has been sentenced to three years in prison for violating Chinese laws on scientific research and medical management. Two of his colleagues also face prison for genetically engineering human embryos that eventually became the worlds first CRISPRd babies.

The story isnt over: at least one other scientist is eagerly following Hes footsteps in creating gene-edited humans, although he stresses that he wont implant any engineered embryos until receiving regulatory approval.

Biotech stories are rarely this dramatic. But as gene editing tools and assisted reproductive technologies increase in safety and precision, were bound to see ever more mind-bending headlines. Add in a dose of deep learning for drug discovery and synthetic biology, and its fair to say were getting closer to reshaping biology from the ground upboth ourselves and other living creatures around us.

Here are two stories in biotech were keeping our eyes on. Although successes likely wont come to fruition this year (sorry), these futuristic projects may be closer to reality than you think.

The idea of human-animal chimeras immediately triggers ethical aversion, but the dream of engineering replacement human organs in other animals is gaining momentum.

There are two main ways to do this. The slightly less ethically-fraught idea is to grow a fleet of pigs with heavily CRISPRd organs to make them more human-like. It sounds crazy, but scientists have already successfully transplanted pig hearts into baboonsa stand-in for people with heart failurewith some recipients living up to 180 days before they were euthanized. Despite having foreign hearts, the baboons were healthy and acted like their normal buoyant selves post-op.

But for cross-species transplantation, or xenotransplants to work in humans, we need to deal with PERVsa group of nasty pig genes scattered across the porcine genome, remnants of ancient viral infections that can tag along and potentially infect unsuspecting human recipients.

Theres plenty of progress here too: back in 2017 scientists at eGenesis, a startup spun off from Dr. George Churchs lab, used CRISPR to make PERV-free pig cells that eventually became PERV-free piglets after cloning. Then last month, eGenesis reported the birth of Pig3.0, the worlds most CRISPRd animal to further increase organ compatibility. These PERV-free genetic wonders had three pig genes that stimulate immunorejection removed, and nine brand new human genes to make themin theorymore compatible with human physiology. When raised to adulthood, pig3.0 could reproduce and pass on their genetic edits.

Although only a first clinical propotype that needs further validation and refinement, eGenesis is hopeful. According to one (perhaps overzealous) estimate, the first pig-to-human xenotranplant clinical trial could come in just two years.

The more ethically-challenged idea is to grow human organs directly inside other animalsin other words, engineer human-animal hybrid embryos and bring them to term. This approach marries two ethically uncomfortable technologies, germline editing and hybrids, into one solution that has many wondering if these engineered animals may somehow receive a dose of humanness by accident during development. What if, for example, human donor cells end up migrating to the hybrid animals brain?

Nevertheless, this year scientists at the University of Tokyo are planning to grow human tissue in rodent and pig embryos and transplant those hybrids into surrogates for further development. For now, bringing the embryos to term is completely out of the question. But the line between humans and other animals will only be further blurred in 2020, and scientists have begun debating a new label, substantially human, for living organisms that are mainly human in characteristicsbut not completely so.

With over 800 gene therapy trials in the running and several in mature stages, well likely see a leap in new gene medicine approvals and growth in CAR-T spheres. For now, although transformative, the three approved gene therapies have had lackluster market results, spurring some to ponder whether companies may cut down on investment.

The research community, however, is going strong, with a curious bifurcating trend emerging. Let me explain.

Genetic medicine, a grab-bag term for treatments that directly change genes or their expression, is usually an off-the-shelf solution. Cell therapies, such as the blood cancer breakthrough CAR-T, are extremely personalized in that a patients own immune cells are genetically enhanced. But the true power of genetic medicine lies in its potential for hyper-personalization, especially when it comes to rare genetic disorders. In contrast, CAR-Ts broader success may eventually rely on its ability to become one-size-fits-all.

One example of hyper-tailored gene medicine success is the harrowing story of Mila, a six-year-old with Batten disease, a neurodegenerative genetic disorder that is always fatal and was previously untreatable. Thanks to remarkable efforts from multiple teams, however, in just over a year scientists developed a new experimental therapy tailored to her unique genetic mutation. Since receiving the drug, Milas condition improved significantly.

Milas case is a proof-of-concept of the power of N=1 genetic medicine. Its unclear whether other children also carry her particular mutationBatten has more than a dozen different variants, each stemming from different genetic miscodingor if anyone else would ever benefit from the treatment.

For now, monumental costs and other necessary resources make it impossible to pull off similar feats for a broader population. This is a shame, because inherited diseases rarely have a single genetic cause. But costs for genome mapping and DNA synthesis are rapidly declining. Were starting to better understand how mutations lead to varied disorders. And with multiple gene medicines, such as antisense oligonucleotides (ASOs) finally making a comeback after 40 years, its not hard to envision a new era of hyper-personalized genetic treatments, especially for rare diseases.

In contrast, the path forward for CAR-T is to strip its personalization. Both FDA-approved CAR-T therapies require doctors to collect a patients own immune T cells, preserved and shipped to a manufacturer, genetically engineered to boost their cancer-hunting abilities, and infused back into patients. Each cycle is a race against the cancer clock, requiring about three to four weeks to manufacture. Shipping and labor costs further drive up the treatments price tag to hundreds of thousands of dollars per treatment.

These considerable problems have pushed scientists to actively research off-the-shelf CAR-T therapies, which can be made from healthy donor cells in giant batches and cryopreserved. The main stumbling block is immunorejection: engineered cells from donors can cause life-threatening immune problems, or be completely eliminated by the cancer patients immune system and lose efficacy.

The good news? Promising results are coming soon. One idea is to use T cells from umbilical cord blood, which are less likely to generate an immune response. Another is to engineer T cells from induced pluripotent stem cells (iPSC)mature cells returned back to a young, stem-like state. A patients skin cells, for example, could be made into iPSCs that constantly renew themselves, and only pushed to develop into cancer-fighting T cells when needed.

Yet another idea is to use gene editing to delete proteins on T cells that can trigger an immune responsethe first clinical trials with this approach are already underway. With at least nine different off-the-shelf CAR-T in early human trials, well likely see movement in industrialized CAR-T this year.

Theres lots of other stories in biotech we here at Singularity Hub are watching. For example, the use of AI in drug discovery, after years of hype, may finally meet its reckoning. That is, can the technology actually speed up the arduous process of finding new drug targets or the design of new drugs?

Another potentially game-changing story is that of Biogens Alzheimers drug candidate, which reported contradicting results last year but was still submitted to the FDA. If approved, itll be the first drug to slow cognitive decline in a decade. And of course, theres always the potential for another mind-breaking technological leap (or stumble?) thats hard to predict.

In other words: we cant wait to bring you new stories from biotechs cutting edge in 2020.

Image Credit: Image by Konstantin Kolosov from Pixabay

Go here to see the original:
The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub

Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami – Yahoo Finance

2020 Honorees include Cystic Fibrosis Foundation, Emily Whitehead Foundation, Gift of Life Marrow Registry and Ret. Major General Bernard Burn Loeffke (US Military)

Miami, FL, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The formal ceremony of the 2020 Stem Cell and Regenerative Medicine Action Awards will take place at a gala reception and dinner on January 23, during the 15th annual World Stem Cell Summit (WSCS) at the Hyatt Regency in Miami. Since 2005, the nonprofit Regenerative Medicine Foundation (RMF) (formerly Genetics Policy Institute) has recognized the stem cell and regenerative medicine community's leading innovators, leaders, and champions through its annual awards reception.

Bernard Siegel, Executive Director of Regenerative Medicine Foundation and founder of the World Stem Cell Summit, said, The 2020 Action Awards will recognize three important organizations that are positively impacting the emerging field of regenerative medicine. We will also honor a retired Major General, who has capped off his military and diplomatic career by promoting the cause of world peace through medicine. All of these distinguished honorees will be recognized for their devotion to improving health and developing cures through advocacy, innovation, leadership and inspiration. In addition, the wounded warrior veterans community of South Florida will also receive special recognition at the event.

Meet the 2020 Stem Cell & Regenerative Medicine Action Award Honorees:

Innovation Award: With the motto, We will not rest until we find a cure, the Cystic Fibrosis Foundation is geared towards the successful development and delivery of treatments, therapies and a cure for every person with cystic fibrosis. CF Foundation has added decades to the lives of people with the disease as a direct result of advances in treatment and care made possible through its innovative business model- venture philanthropy. The Foundation recently unveiled its Path to a Cure research agenda aimed at addressing the root genetic cause of the disease and is currently funding industry programs aimed at gene delivery with the goal of progressing into clinical studies in 2021.

Inspiration Award: Emily Whitehead Foundation is a nonprofit organization committed to raising funds to invest in the most promising pediatric cancer research. Tom and Kari Whitehead founded EWF in honor of their daughter Emily, the first child in the world to receive CAR T-cell therapy, training her own cells to fight cancer. Her inspiring story focused public attention on thepotential for cancer immunotherapy to transform cancer treatment,as well as the need to support lifesaving cancer immunotherapy research. The foundation provides support to pediatric cancer patients and promotes awareness of the disease through education and sharing other inspiring stories.

Advocacy Award: Gift of Life Marrow Registry was established in 1991 by Jay Feinberg and his family after Jay received a life-saving bone marrow transplant. Gift of Life is dedicated to saving lives and facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, sickle cell and other diseases. In 2019, Gift of Life opened the worlds first apheresis center fully integrated within a registry, the Dr. Miriam and Sheldon G. Adelson Gift of Life-Be The Match Stem Cell Collection Center. With the collection center and rapidly expanding donor database, Gift of Life will launch a biobank to advance cellular therapies using allogeneically sourced cells in 2020.

Leadership Award: Ret. Major General Bernard Burn Loeffke, PhD (US Military) is a highly decorated Special Forces officer, diplomat and medical officer.He survived two helicopter crashes and was wounded in combat. After the Vietnam War, he served as the Army Attach at theU.S. Embassy in Moscow, first Defense Attach at the U.S Embassy in Beijing, a staff officer in theWhite House, and Director of the Commission onWhite House Fellows. His last command was Commanding General of Army South. After 35 years in the military, he became a medical officer traveling the world on relief missions to third and fourth world countries. Presently, at age 85, he champions the hydrocephalus and wounded warrior communities. He continues to serve as an inspiration and supporter of building peaceful international relations through medical partnerships and played a pivotal role as a keynote speaker at the inaugural 2019 World Stem Cell Summit CHINA.He is called the Peace General in Latin America. In China, he is simply known as The General, our Friend.

Story continues

To learn more about past honorees and details for sponsoring or attending the upcoming 2020 Stem Cell and Regenerative Medicine Action Awards dinner, please visit, https://www.worldstemcellsummit.com/stem-cell-action-awards/

About the World Stem Cell Summit (WSCS)

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About the Regenerative Medicine Foundation (RMF)

The nonprofit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF unites the worlds leading researchers, medical centers, universities, labs, businesses, funders, policymakers, experts in law, regulation and ethics, medical philanthropies, and patient organizations. We maintain a trusted network of leaders and pursue our mission by producing our flagship World Stem Cell Summit series of conferences and public days, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, supporting our official journal partner STEM CELLS Translational Medicine (SCTM), promoting solution-focused policy initiatives both nationally and internationally and creating STEM/STEAM educational projects. For more information about RMF, please visit: http://www.regmedfoundation.org.

Attachments

Joseph DawsonRegenerative Medicine Foundation561-906-4755joseph@regmedfoundation.org

Here is the original post:
Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami - Yahoo Finance

John Theurer Cancer Center Announces Appointment of Five New Physicians – Newswise

MEDIA CONTACT

Available for logged-in reporters only

John Theurer Cancer Center Announces Appointment of Five New Physicians

Cancer doctors bolster center's stem cell transplantation, blood cancer, and thoracic cancer programs.

Newswise HACKENSACK, N.J.,January 9, 2019 Five new physicians have joined the medical staff at John Theurer Cancer Center at Hackensack University Cancer Center in New Jersey:

Hyung C. Suh, MD, PhD, is a hematologist-oncologist who joined the Stem Cell Transplantation and Cellular Therapy program. Dr. Suh specializes in the care of people with blood cancers (such as leukemia, lymphoma, and multiple myeloma) and in the use of stem cell transplantation, cellular therapy, and immunotherapy to treat these cancers. He is also an experienced biomedical scientist with expertise in hematology-oncology research and the translation of research findings from the laboratory to the patients they may help. A native of South Korea, Dr. Suh graduated from Yonsei University College of Medicine in Seoul, where he earned his MD and PhD degrees. He completed internal medicine residencies at Yonsei University College of Medicine and Cleveland Clinic Foundation and hematology-oncology fellowships at Yonsei University College of Medicine and UCLA School of Medicine.

Gurbakhash Kaur, MD, is a hematologist-oncologist who specializes in hematology-oncology, especially the treatment of multiple myeloma. She is especially interested in the application of novel immunotherapies to treat cancer, including multiple myeloma. Dr. Kaur received her medical degree from Drexel University College of Medicine and completed her internal medicine residency at Tufts Medical Center. She then went on to complete a fellowship in hematology-oncology at Montefiore Medical Center.

Sukhdeep Kaur, MD, is a hematologist-oncologist who specializes in stem cell transplantation including allogeneic transplants (from a donor) and autologous ("self") transplants for blood cancers and blood diseases. She also oversees the use of cellular therapies in patients, including CAR T-cell therapy an innovative treatment which trains a patient's white blood cells (called T cells) to find and destroy cancer cells. Dr. Kaur received her medical degree from Ross University and completed her internal medicine residency at Drexel University College of Medicine, serving as Chief Resident in her final year. She then went on to complete a fellowship in hematology-oncology at Robert Wood Johnson University Hospital/Cancer Institute of New Jersey, where she was Chief Fellow.

Andrew Ip, MD, MS, is a hematologist-oncologist who specializes in the care of patients with lymphoma and multiple myeloma. In his research, Dr. Ip is part of John Theurer Cancer Center's Outcomes Division. He is interested in utilizing population science to see the "big picture" of cancer care in order to enhance the lives of patients and their families. He also has an interest in using digital health technology to promote improved cancer outcomes, having piloted an Apple Watch physical activity intervention for people with cancer. Dr. Ip received his medical degree from Jefferson Medical College (now Sidney Kimmel Medical College at Thomas Jefferson University). He completed his internal medicine residency at Emory University School of Medicine, where he was Chief Medical Resident in his last year. He then went on to complete a fellowship in hematology and medical oncology at the Winship Cancer Institute at Emory, where he was Chief Fellow for his final year.

Kaushal Parikh, MBBS, is a medical oncologist who specializes in the treatment of patients with thoracic cancers, such as lung cancer, thymoma, and mesothelioma. He is also involved in drug development and early-phase clinical trials, particularly through John Theurer Cancer Center's robust Phase I clinical trials program. He and his colleagues are working to expand the translational research program so that more findings from the laboratory can be translated to the clinic to help patients. Dr. Parikh received his medical degree from Topiwala National Medical College in Mumbai, India. He completed his internal medicine residency and hematology-oncology fellowship at New York Medical College, where he was Chief Hematology and Oncology Fellow for his final year. He then completed a fellowship in thoracic oncology at the Mayo Clinic School of Medicine in Minnesota.

For more information, contact Mary McGeever, Hackensack University Medical Center Communications and Public Relations Department, at 551-996-1730 (office), 551-795-1675 (cell) or Mary.McGeever@HackensackMeridian.org

ABOUTJOHN THEURER CANCER CENTERATHACKENSACKUNIVERSITY MEDICAL CENTER

John Theurer Cancer CenteratHackensack University Medical CenterisNew Jersey'slargest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in theNew Jersey/New York metropolitan area turn toJohn Theurer Cancer Centerfor cancer care than to any other facility inNew Jersey. Housed withinHackensack University Medical Center, a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguishJohn Theurer Cancer Centerfrom other facilities.For additional information, please visitwww.jtcancercenter.org.

About Hackensack Meridian Hackensack University Medical Center

Hackensack Meridian Hackensack University Medical Center, a 781-bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the countys first hospital, it is now part of the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care, which is comprised of 35,000 team members and more than 7,000 physicians. Hackensack University Medical Center is ranked #2 in New Jersey and #59 in the country in U.S. News & World Reports 2019-20 Best Hospital rankings and is ranked high-performing in the U.S. in colon cancer surgery,lung cancersurgery,COPD, heart failure, heart bypass surgery, aortic valve surgery,abdominal aortic aneurysm repair, knee replacement and hip replacement. Out of 4,500 hospitals evaluated, Hackensack is one of only 57 that received a top rating in all nine procedures and conditions. Hackensack University Medical Center is one of only five major academic medical centers in the nation to receive Healthgrades Americas 50 Best Hospitals Award for five or more years in a row. Beckers Hospital Review recognized Hackensack University Medical Center as one of the 100 Great Hospitals in America 2018. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 26 Gold Seals of Approval by The Joint Commission more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet recognized hospital for nursing excellence; receiving its sixth consecutive designation in 2019. Hackensack University Medical Center has created an entire campus of award-winning care, including: John Theurer Cancer Center, a consortium member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Womens and Childrens Pavilion, which houses the Joseph M. Sanzari Childrens Hospital and Donna A. Sanzari Womens Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guides list of Top 10 Green Hospitals in the U.S. Hackensack University Medical Center is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to THE NORTHERN TRUST PGA Golf Tournament. It remains committed to its community through fundraising and community events especially the Tackle Kids Cancer Campaign providing much needed research at the Childrens Cancer Institute housed at the Joseph M. Sanzari Childrens Hospital. To learn more, visit http://www.HackensackUMC.org.

See the rest here:
John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise

Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis Point of Care…

First collaboration project focused on developing and commercializing lentiviral manufacturing system

GERMANTOWN, Md., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland, Inc., today announced the addition of the University of California, Davis (UC Davis) to its Point of Care (POCare) Network. Under the collaboration agreement, UC Davis Health will utilize Orgenesis POCare platform to develop, commercialize and supply cell and gene products and therapies. Orgenesis POCare Network enables hospitals to design and manage localized clean rooms, implementing Orgenesis proprietary automated, closed systems and know-how to process select cell therapies at each point-of-care site for the treatment of patients.

The first collaboration under the agreement involves scaling up and integrating UC Davis lentiviral vector process as part of the Orgenesis POCare platform for localized, development and processing of cell and gene therapies for treating patients. The UC Davis GMP facility has developed a small-intermediate scale, high quality vector process that has been successfully utilized to manufacture lentiviral vectors in several clinical trials, including manufacturing of CAR T cell therapies. Orgenesis POCare platform, which combines processing and therapeutic technologies, is designed to allow for the efficient production of high quality, affordable cell and gene based products. Upon successful completion of the collaboration, Orgenesis and UC Davis plan to pursue further commercialization of the technology and expand the processing and supply of their products under development at the UC Davis site. Lentivirus is a family of viruses that insert their DNA into the host cells' genome. Lentiviral vectors are increasingly utilized in cell and gene therapy as a method for inserting, modifying, or deleting specific genes within cells.

Vered Caplan, CEO of Orgenesis, stated, We are delighted to add UC Davis to our POCare Network, which will allow us to collaborate with the university to develop and supply therapeutics within the point-of-care setting in general and specifically in our need for virus supply. Additionally, we look forward to leveraging our POCare platform to assist UC Davis in expanding their ability to address the worldwide shortages of lentiviral vectors. Their new system is designed to address the global need for a more efficient, large scale vector manufacturing processes in an efficient manner. We believe this partnership further validates the significant value proposition of our POCare platform.

Adjunct Professor Gerhard Bauer, Director of the GMP Facility at UC Davis, commented, We, at the UC Davis Health, in the Stem Cell Program and in the GMP Facility, are committed to bringing these novel cell and gene therapy based treatments to patients in need and making them affordable.

Professor Jan A. Nolta, Director of the Stem Cell Program and the Gene Therapy Center at UC Davis Health, added, We look forward to leveraging Orgenesis expertise to accelerate the development and commercialization of our lentiviral vector manufacturing system, which addresses a significant unmet need in the market for an efficient and scalable manufacturing process.

About Orgenesis

Orgenesis is a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates through two platforms: (i) a point-of-care (POCare) cell therapy platform (PT) and (ii) a Contract Development and Manufacturing Organization (CDMO) platform conducted through its subsidiary, Masthercell Global. Through its PT business, the Companys aim is to further the development of Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the Companys CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies. Additional information is available at: http://www.orgenesis.com.

Story continues

About UC Davis Stem Cell Program and Gene Therapy Center

UC Davis Stem Cell Program brings together physicians, research scientists, biomedical engineers and a range of other experts and collaborative partners at its Institute for Regenerative Cures, which is located on the universitys Sacramento campus. The $62 million facility, which was supported by the California Institute for Regenerative Medicine (CIRM), is the hub for collaborative, team-oriented science that is advancing breakthrough discoveries designed to bring stem cell therapies and cures to patients everywhere.

The UC Davis Gene Therapy Center brings together a uniquely comprehensive and established interdisciplinary network of experts and resources to lead the field of gene therapy through research, manufacturing, training and policy. The Gene Therapy Center offers expertise and state-of-the-art facilities and equipment including one of the largest university-based Good Manufacturing Practice (GMP) facilities and a Viral Vector Core.

About UC Davis

UC Davis is one of the top public universities in the United States. Since opening in 1908, it has been known for standout academics, sustainability and Aggie Pride as well as valuing the Northern California lifestyle. These themes are woven into its 100-plus-year history and its reputation for solving problems related to food, health, the environment and society. The universitys health system is based in Sacramento and provides the region's only academic health center. UC Davis Health is focused on discovering and sharing knowledge and providing the highest quality of care. It is a hub of innovation that encompasses UC Davis Medical Center, UC Davis School of Medicine, The Betty Irene Moore School of Nursing at UC Davis and UC Davis Medical Group.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the success of our reorganized CDMO operations, the success of our partnership with Great Point Partners, our ability to achieve and maintain overall profitability, the sufficiency of working capital to realize our business plans, the development of our POCare strategy, our trans-differentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended November 30, 2018, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for Orgenesis:Crescendo Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com

Original post:
Orgenesis Announces Addition of University of California, Davis, to its Point of Care Network; UC Davis Health to Utilize Orgenesis Point of Care...

Aspen Neuroscience Announces Board of Directors and Scientific Advisory Board – PRNewswire

SAN DIEGO, Jan. 9, 2020 /PRNewswire/ -- Aspen Neuroscience, Inc.,a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, has announced the members of its Board of Directors and Scientific Advisory Board. These boards bring together many of the world's most distinguished industry and academic minds to deliver Aspen's personalized cell therapy to persons suffering with Parkinson disease.

"We are proud of the talented groups we have assembled," said Aspen CEO Howard Federoff, MD, PhD. "They bring a wealth of insights and experience in biomedical research and therapeutic development that will be essential for our success. Together, we are motivated to bring best-in-class treatments to Parkinson patients as rapidly as possible. They have waited long enough."

Last month, Aspen announced it has raised $6.5 million in seed fundingand unveiled its plans to use neurons derived from induced pluripotent stem cells (iPSCs) to combat the debilitating motor symptoms of Parkinson disease. These iPSCs will be created from each patient's own cells and then differentiated into dopamine-producing neurons, replacing the critical cells lost in Parkinson disease. Because the therapy is created from each patient's own tissue, no immunosuppression will be necessary.

"The creation of our esteemed Board of Directors and Scientific Advisory Board is an important step for Aspen's future development as it will help guide the company's progress toward regulatory approval," said Kim P. Kamdar, PhD, Aspen Board Chair and Partner at Domain Associates. "The members of each board bring significant expertise, complementary skills and an external perspective, which will be very valuable in informing Aspen's strategy."

Aspen's Board of Directors includes well-known industry veterans and financial minds from leading venture capital firms that are poised todirect the growth of Aspen through clinical trials and regulatory approval.

Aspen Neuroscience Board of Directors

The Scientific Advisory Board consists of leaders in the fields of bioethics, regenerative medicine clinical trials, autologous iPSC-based therapy, and Parkinson disease neuron replacement and neuroimaging.

Aspen Neuroscience Scientific Advisory Board

The newly established boards will join Aspen's impressive leadership team: Howard J. Federoff, MD, PhD, Chief Executive Officer; Jeanne Loring, PhD, Chief Scientific Officer; Edward Wirth, MD, PhD, Chief Medical Officer; Jay Sial, Chief Financial Officer; Andres Bratt-Leal, PhD, Vice President of Research and Development; Thorsten Gorba, PhD, Senior Director of Manufacturing; and Naveen M. Krishnan, MD, MPhil, Senior Director of Corporate Development.

About Aspen NeuroscienceAspen Neuroscience, Inc., is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.

SOURCE Aspen Neuroscience

https://www.aspenneuroscience.com

The rest is here:
Aspen Neuroscience Announces Board of Directors and Scientific Advisory Board - PRNewswire

How Kyoto Is Rebuilding Itself As A Nanotech And Regenerative Medicine Powerhouse – Forbes

As humans continue to pump more and more carbon dioxide into the atmosphere, concerns about global warming and climate change continue to grow. But what if that CO2 could be turned into a source of energy? One startup in Kyoto has developed cutting-edge nano-materials that could trap atmospheric CO2 and harness it as a power source. Its one way that Japans ancient capital is harnessing its large scientific and biomedical potential to address environmental and social problems.

Panning for invisible gold

Porous coordination polymers can be a form of carbon-capture technology, says discoverer Susumu Kitagawa, second from left, with (left to right) Atomis CTO Masakazu Higuchi, CEO Daisuke Asari, R&D officer Kenji Sumida, and COO Dai Kataoka.

Atomis is a new materials company that was spun off from Kyoto University. Founded in 2015 following government-supported research, its business is based on studies led by Susumu Kitagawa, a professor in the universitys Institute for Advanced Study. Its core technology is the production of materials comprising extremely small void spaces that can trap gases, including CO2. A breakthrough discovery in 1997 by Kitagawa, who has been considered a contender for the Nobel Prize in Chemistry, these porous coordination polymers (PCPs, aka metal-organic frameworks) have enormous potential as tools to precisely control gases.

Humans have used the principle behind PCPs for thousands of years. They work the same way that a hunk of charcoal traps ambient odor molecules in its large surface area, but PCPs are many times more powerful. To the naked eye, PCPs look like powders, pellets or granules of various colors, shapes and sizes. But if you were to zoom in, you would see that PCPs are sponge-like materials with pores the size of a nanometer, or one billionth of a meter. They can be designed as scaffoldlike 3D structures from metals and organic ligands, and can be used for storage, separation and conversion of molecules.

These materials are unique in that we can design the shapes and chemical properties of the pores to suit specific applications, and some of the materials have flexible structures, which can potentially provide them with even more advanced features, says Daisuke Asari, president and CEO of Atomis. The company is basically the only business in Japan working with these materials in an industrial context. Collaborating with Kitagawa is a big advantage over foreign rivals, adds Kenji Sumida, executive officer for R&D.

One challenge related to these nanomaterials is that its difficult and costly to produce more than a few kilograms per day. Massively scaling production so that PCPs can be used to fight climate change is one reason that Atomis was founded, says Atomis founder and CTO Masakazu Higuchi, one of Kitagawas collaborators. The firm is developing solid-state techniques and making capital investments to increase PCP production capacity. Meanwhile, Atomis has developed products that harness the groundbreaking potential of PCPs, including Cubitan, a compact and lightweight gas cylinder for industrial and consumer use packed with smart features, such as the ability to notify users when the amount of reserve gas becomes low.

When viewed without special equipment, PCPs look like powders, pellets or granules of various colors, shapes and sizes, but they are sponge-like materials with countless pores the size of a nanometer.

Kitagawa has his sights on the bigger picture. He believes PCPs can be used as a form of carbon-capture technology, allowing the synthesis of methanol, an energy source. Thats why he calls CO2 invisible gold.

In ancient China, Taoist mystics were said to live in the mountains and survive simply on mist, which consists of water, oxygen and CO2, says Kitagawa. They were taking something valueless and using it for energy. Similarly, PCPs can control gases that humans cannot use and turn them into something beneficial, for instance absorbing CO2 in the air and turning into methanol and other hydrocarbon materials.

Building a regenerative medicine Silicon Valley

Atomis is one of many science startups in Kyoto that have benefitted from collaborative research between industry and government. Its part of a growing startup industry in Japan, where total funding for new companies reached a record high of 388 billion yen in 2018, up from 64.5 billion yen in 2012, according to Japan Venture Research. One driver for this expansion is science and technology discoveries.

While it may be known for its traditional culture, Kyoto has a strong pedigree in scientific research. It is home to 38 universities and about 150,000 students, which form a large pool of institutional knowledge, experience and talent. Many recent Nobel laureates either graduated from or taught at Kyoto University, including professors Tasuku Honjo and Shinya Yamanaka, who won the Nobel Prize for Physiology or Medicine in 2018 and 2012, respectively. Working on discoveries by Yamanaka, Megakaryon has become a world leader in creating artificial blood platelets made from synthetic stem cells.Theres also a large group of high-tech companies that have carved out niches for themselves internationally.

Kyoto is a unique city in that it has an independent spirit that is similar to the U.S. West Coast, says Eiichi Yamaguchi, a professor at Kyoto University who has founded four companies.

Kyoto companies like Murata Manufacturing, Horiba, Shimadzu, and Kyocera have a global market and theyre competing with China, says Eiichi Yamaguchi, a professor at Kyoto University who has founded four companies. Thats the difference with companies in Tokyo, which are more domestically oriented.

Yamaguchi has authored several books on innovation, and says there is a growing awareness of the importance of collaborative research and entrepreneurship in Kyoto. He cites a recently formed cooperative group of seven university chairpersons and presidents from leading materials and biosciences companies that meets to discuss issues such as fostering new technologies, for instance building high-speed hydrogen fueling systems.

Kyoto is a unique city in that it has an independent spirit that is similar to the U.S. West Coast, says Yamaguchi. Kyoto is only a fraction of the size of Tokyo, but if you take a stand here, people will pay attention.

Another group that is promoting local high-tech business is Innovation Hub Kyoto. Its an open innovation facility based in the Kyoto University Graduate School of Medicine aimed at commercializing research from the university. Steps away from Kyotos historic Kamo River, its geared to researchers, investors, startups, and established companies working in the field of medical innovation including device development and drug discovery. This is where Japanese researchers are trying to build a Silicon Valley of regenerative medicine.

Tenants at Innovation Hub Kyoto can use this wet lab for research.

Part of the Kyoto University Medical Science and Business Liaison Organization, the hub was established about 15 years ago and opened a new building in 2017 with the support of the Ministry of Education, Culture, Sports, Science and Technology. The structure has a variety of labs, including ones meeting biosafety level P2 and for animal experiments.

Its tough for startups in Japan to access to animal laboratories like the one we have, says hub leader Yutaka Teranishi, a professor in the Graduate School of Medicine who estimates that some 50% of university researchers want to work with industry, up from 10% a few years ago. Were focused on university startups because its very difficult for them to develop drugs from just an alliance between companies and universities.

About 28 companies are tenants at Innovation Hub Kyoto. They include major brands such as Shimadzu and Nippon Boehringer Ingelheim as well as younger businesses. One is AFI, founded in 2013 and focused on fluid, electric filtering and sorting (FES) technology that can be used for applications ranging from food safety inspections to rapid diagnosis of disease to regenerative medicine.

Tomoko Bylund heads the Japan office of CELLINK, a Swedish bioprinting and bioink company that is a tenant at Innovation Hub Kyoto.

Another tenant is CELLINK, a Swedish bioprinting and bioink company headed in the Japan by Tomoko Bylund. Using its products, researchers can print body parts with human cells for drug and cosmetics testing. In 2019, the first 3D print of a human cornea in the U.S. was accomplished with the companys BIO X Bioprinter.

iHeart Japan is also a tenant. It was established in 2013 as a regenerative medicine business and is aiming to address a major shortage in the Japanese medical system: only about 40 out of 200,000 people on national waiting lists can receive donor hearts every year. The company is developing innovative medical products such as multi-layered cardiac cell sheets derived from synthetic stem cells. The Hub basis its success in fostering companies on its diversity and the business environment in Kyoto.

We have people from different backgrounds here who are exchanging cultures and experimental results, and this diversity is powering innovation here, says Teranishi. There are many traditional industries in Kyoto, and though people say its a conservative city, these companies have survived because theyre open to new technologies and have taken the time to choose which ones can help them. Thats how this city and its businesses have lasted for more than 1,000 years.

Diversity is powering innovation here, says Yutaka Teranishi, center, head of Innovation Hub Kyoto, with Kyoto University professor Hirokazu Yamamoto, left, and Graduate School of Medicine lecturer Taro Yamaguchi, right.

To learn more about Atomis, click here.

To learn more about Innovation Hub Kyoto, click here.

See the original post:
How Kyoto Is Rebuilding Itself As A Nanotech And Regenerative Medicine Powerhouse - Forbes